[
  {
    "ts": "2026-01-13T12:47:13+00:00",
    "headline": "JPM26: HIV pipeline dosing optionality gives Gilead advantage",
    "summary": "Speaking at the J.P. Morgan Healthcare Conference 2026, CEO Daniel O’Day said that the company has seven pipeline drugs for HIV.",
    "url": "https://www.pharmaceutical-technology.com/news/jpm26-hiv-pipeline-dosing-optionality-gives-gilead-advantage/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "81db00cd-bf57-3dab-bd96-c6b0fb6df5e5",
      "content": {
        "id": "81db00cd-bf57-3dab-bd96-c6b0fb6df5e5",
        "contentType": "STORY",
        "title": "JPM26: HIV pipeline dosing optionality gives Gilead advantage",
        "description": "",
        "summary": "Speaking at the J.P. Morgan Healthcare Conference 2026, CEO Daniel O’Day said that the company has seven pipeline drugs for HIV.",
        "pubDate": "2026-01-13T12:47:13Z",
        "displayTime": "2026-01-13T12:47:13Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/b4c10de7a616516f99390d149983344e",
          "originalWidth": 1024,
          "originalHeight": 683,
          "caption": "Gilead's CEO Daniel O'Day presented at the J.P. Morgan Healthcare Conference on 12 January. Image credit:\tETIENNE LAURENT / AFP via Getty Images",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GLxUcYtrcjHMAunk2gpDtQ--~B/aD02ODM7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/b4c10de7a616516f99390d149983344e.cf.webp",
              "width": 1024,
              "height": 683,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yzM2ayO4AlevesHckigNbA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/b4c10de7a616516f99390d149983344e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/jpm26-hiv-pipeline-dosing-optionality-gives-gilead-advantage/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-hiv-pipeline-dosing-optionality-124713655.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]